

# Grace Lai-Hung Wong

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3766779/grace-lai-hung-wong-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

375 papers	18,327 citations	75 h-index	124 g-index
422 ext. papers	22,883 ext. citations	6.4 avg, IF	6.84 L-index

#	Paper	IF	Citations
375	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100441	10.3	1
374	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , <b>2022</b> , 2022, 1-13	1	
373	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> , 55, 616-617	6.1	0
372	Risks of post-colonoscopy polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. <i>Gut</i> , <b>2022</b> , 71, 100-110	19.2	7
371	Chronic hepatitis B and D <b>2022</b> , 447-455		
370	Reply.. <i>Hepatology</i> , <b>2022</b> ,	11.2	
369	Management of hepatitis B virus reactivation due to treatment of COVID-19.. <i>Hepatology International</i> , <b>2022</b> , 16, 257	8.8	1
368	Stopping 5-Aminosalicylic Acid in Ulcerative Colitis Patients in Corticosteroid-free remission is not associated with Increased Risk of Flare: A Territory-wide population-based cohort study.. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2022</b> ,	4	1
367	Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.. <i>World Journal of Gastroenterology</i> , <b>2022</b> , 28, 1563-1573	5.6	1
366	How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?. <i>Journal of Hepatology</i> , <b>2022</b> , 76, 1249-1262	13.4	6
365	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. <i>BMJ Open</i> , <b>2021</b> , 11, e052310	3	6
364	ACE inhibitors prevent liver-related events in non-alcoholic fatty liver disease.. <i>Hepatology</i> , <b>2021</b> ,	11.2	5
363	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 321-331	6.1	5
362	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 984-993	0.7	10
361	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> ,	6.9	2
360	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. <i>BMJ Open</i> , <b>2021</b> , 11, e052310	3	4
359	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , <b>2021</b> , 16, 48	8.8	2

358	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD.. <i>Metabolism: Clinical and Experimental</i> , <b>2021</b> , 128, 154958	12.7	0
357	Association of genetic variations with NAFLD in lean individuals. <i>Liver International</i> , <b>2021</b> ,	7.9	4
356	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	6
355	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1950-1958.e7	6.9	8
354	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2161-2171.e5	6.9	36
353	Reply to Hoffmann and Wolf. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e1782-e1783	11.6	
352	Explainable Uncertainty-Aware Convolutional Recurrent Neural Network for Irregular Medical Time Series. <i>IEEE Transactions on Neural Networks and Learning Systems</i> , <b>2021</b> , 32, 4665-4679	10.3	3
351	Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 543-550	4	14
350	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1212-1223	6	1
349	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 185-198	18.8	36
348	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , <b>2021</b> , 11, 5416	4.9	2
347	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2684-2685	6.9	
346	Neurological diseases and risk of mortality in patients with COVID-19 and SARS: a territory-wide study in Hong Kong. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2021</b> , 92, 1356-1358	5.5	1
345	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab205	1	2
344	Implications of COVID-19 for patients with pre-existing digestive diseases: an update. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 258-260	18.8	3
343	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 1890-1899	7	4
342	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
341	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 470-480	6.1	6

340	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , <b>2021</b> , 74, 1750-1765	11.2	12
339	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 136-145.e6 <sup>19</sup>	6.9	6
338	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , <b>2021</b> , 70, 733-742	19.2	65
337	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e466-e475	11.6	13
336	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 73, 2238-2250	11.2	7
335	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 84, 68-73	3.9	1
334	Continuous Positive Airway Pressure Does Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea. A Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 493-501	10.2	6
333	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , <b>2021</b> , 15, 71-81	8.8	4
332	HCV elimination in Hong Kong - Non-government organisation (NGO) activities. <i>Global Health &amp; Medicine</i> , <b>2021</b> , 3, 283-287	2.4	0
331	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1274-1283	0.7	7
330	Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. <i>Gut</i> , <b>2021</b> , 70, 698-706	19.2	312
329	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> ,	12.7	8
328	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00300	4.2	4
327	Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 87	18.8	
326	Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong.. <i>Kidney360</i> , <b>2021</b> , 2, 721-728	1.8	
325	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00324	4.2	4
324	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. <i>Hong Kong Medical Journal</i> , <b>2021</b> ,	0.7	2
323	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 499-509	6.9	0

322	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , <b>2021</b> , 3, 261-269	1	
321	Differential Impacts of Multimorbidity on COVID-19 Severity across the Socioeconomic Ladder in Hong Kong: A Syndemic Perspective. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	6
320	Reply to Letters to the Editor: Clinical outcomes in COVID-19 patients with current or past hepatitis B virus infection. <i>Hepatology</i> , <b>2021</b> ,	11.2	
319	Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.. <i>Journal of Clinical and Translational Hepatology</i> , <b>2021</b> , 9, 972-982	5.2	1
318	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , <b>2021</b> , 4, e352	2.2	
317	Targeting an energy sensor to prevent energy excess in the liver. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 876-877	18.8	
316	Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
315	Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	3
314	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. <i>Ultrasound in Medicine and Biology</i> , <b>2021</b> , 47, 2803-2820	3.5	10
313	Importance-aware personalized learning for early risk prediction using static and dynamic health data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2021</b> , 28, 713-726	8.6	3
312	Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , <b>2021</b> , 19, 329-337	2.5	3
311	Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	5
310	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 660-666	11.6	13
309	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , <b>2020</b> , 14, 1023-1033	8.8	10
308	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 2210-2219	4	8
307	Temporal matrix completion with locally linear latent factors for medical applications. <i>Artificial Intelligence in Medicine</i> , <b>2020</b> , 107, 101883	7.4	0
306	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page". <i>Journal of Hepatology</i> , <b>2020</b> , 73, 729-730	13.4	
305	Efficient Shapelet Discovery for Time Series Classification. <i>IEEE Transactions on Knowledge and Data Engineering</i> , <b>2020</b> , 1-1	4.2	8

304	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , <b>2020</b> , 50, 1024-1031	5.1	13
303	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 867-875	0.7	13
302	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 899-908	6.9	7
301	Assessment of HCC Risk in Patients with Chronic HBV (REACH, PAGE-B, and Beyond). <i>Current Hepatology Reports</i> , <b>2020</b> , 19, 285-292	1	
300	Modelling NAFLD disease burden in four Asian regions-2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 801-811	6.1	31
299	Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. <i>Clinical Microbiology Reviews</i> , <b>2020</b> , 33,	34	82
298	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , <b>2020</b> , 5, 1129-1138	4.1	6
297	Macromolecular proton fraction mapping based on spin-lock magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , <b>2020</b> , 84, 3157-3171	4.4	1
296	Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 315-316	6.1	
295	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1610-1618	4	2
294	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , <b>2020</b> , 72, 1230-1241	11.2	20
293	Reply to Boglione et al. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1584-1585	11.6	
292	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 128	3	4
291	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 904-914	3.4	6
290	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , <b>2020</b> , 26, 128-141	6.9	34
289	Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. <i>Clinical and Molecular Hepatology</i> , <b>2020</b> , 26, 554-561	6.9	1
288	Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 508-508	2.2	
287	Prediction of HCC Using Liver Stiffness Measurements <b>2020</b> , 375-382		



286	Reply. <i>Hepatology</i> , <b>2020</b> , 71, 1134	11.2	
285	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 1206-1213	19.7	1
284	How many deaths are caused by non-alcoholic fatty liver disease in the Asia-Pacific region?. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 103-105	18.8	3
283	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2843-2845.e2	6.9	8
282	The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. <i>Liver International</i> , <b>2020</b> , 40, 549-557	7.9	6
281	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 847-854	13.4	26
280	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 271-280	0.7	45
279	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2020</b> , 40, 581-589	7.9	33
278	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2020</b> , 9, 167-181	9.1	16
277	Reply. <i>Gastroenterology</i> , <b>2020</b> , 158, 2312-2313	13.3	2
276	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 7052-7061	4.8	5
275	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 776-787	18.8	51
274	Collateral Effect of Coronavirus Disease 2019 Pandemic on Hospitalizations and Clinical Outcomes in Gastrointestinal and Liver Diseases: A Territory-wide Observational Study in Hong Kong. <i>Gastroenterology</i> , <b>2020</b> , 159, 1979-1981.e3	13.3	7
273	Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 1023-1036	6.9	4
272	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2020</b> , 40, 2719-2731	7.9	11
271	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , <b>2020</b> , 2, 100152	10.3	8
270	DATA-GRU: Dual-Attention Time-Aware Gated Recurrent Unit for Irregular Multivariate Time Series. <i>Proceedings of the AAAI Conference on Artificial Intelligence</i> , <b>2020</b> , 34, 930-937	5	10
269	Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. <i>Gut</i> , <b>2020</b> , 69, 652-657	19.2	5

268	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , <b>2020</b> , 71, 444-455	11.2	19
267	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , <b>2020</b> , 158, 215-225.e6	13.3	94
266	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , <b>2020</b> , 69, 1116-1126	19.2	12
265	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 389-399	7	22
264	Reply to Sun et al. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 2748-2749	11.6	
263	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 57-66	13.4	25
262	Hepatitis B-management of acute infection and active inflammation in pregnancy-a hepatologist's perspective. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2020</b> , 68, 54-65	4.6	3
261	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 2202-2209	4	3
260	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , <b>2019</b> , 13, 587-598	8.8	22
259	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1141-1151	13.4	51
258	SAT-288-Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e763-e764	13.4	4
257	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , <b>2019</b> , 68, 2057-2064	19.2	65
256	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , <b>2019</b> , 70, 971-981	11.2	18
255	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1641-1647	4	7
254	LBO-03-Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e128	13.4	7
253	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1509-1517	6.1	7
252	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 260-262	18.8	2
251	Current Knowledge of Occult Hepatitis B Infection and Clinical Implications. <i>Seminars in Liver Disease</i> , <b>2019</b> , 39, 249-260	7.3	23



250	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1969-1979	11.6	7
249	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 241-248	4	22
248	FRI-192-Tenofovir disoproxil fumarate treatment in chronic hepatitis B patients with cirrhosis reduces hepatic decompensation, hepatocellular carcinoma and death. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e475	13.4	
247	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1037-1048	6.1	27
246	UA-CRNN: Uncertainty-Aware Convolutional Recurrent Neural Network for Mortality Risk Prediction <b>2019</b> ,		4
245	Unmet need in chronic hepatitis B management. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 172-180	6.9	32
244	Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 912-918	6.1	24
243	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 916-928	0.7	27
242	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , <b>2019</b> , 39, 271-279	7.9	15
241	Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 126-135	3.4	12
240	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. <i>Liver International</i> , <b>2019</b> , 39, 494-502	7.9	1
239	Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues". <i>Journal of Hepatology</i> , <b>2019</b> , 70, 796-797	13.4	1
238	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 361-370	13.4	80
237	Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1787-1794	4	26
236	Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 989-1000	6.1	28
235	Non-invasive assessments for liver fibrosis: The crystal ball we long for. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1009-1015	4	18
234	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 730-737	6.1	42
233	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 765-773.e2	6.9	29

232	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1278-1284	11.6	27
231	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 278-285	13.4	70
230	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 484-491	4	22
229	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 70-85	4	211
228	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 86-98 <sup>4</sup>		71
227	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 934-941	4	7
226	A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: A randomized trial. <i>Liver International</i> , <b>2018</b> , 38, 636-644	7.9	23
225	Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. <i>Liver International</i> , <b>2018</b> , 38, 503-514	7.9	36
224	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , <b>2018</b> , 38, 1911-1919	7.9	8
223	Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 8832-8847	20.1	16
222	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 1349-1356	13.4	96
221	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 984-992	6.1	37
220	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 1239-1249	5.5	47
219	A Hybrid Residual Network and Long Short-Term Memory Method for Peptic Ulcer Bleeding Mortality Prediction <b>2018</b> , 2018, 998-1007	0.7	3
218	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , <b>2018</b> , 52, 347-352	3	15
217	Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. <i>Clinical and Molecular Hepatology</i> , <b>2018</b> , 24, 108-113	6.9	29
216	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. <i>Nature Communications</i> , <b>2018</b> , 9, 5214	17.4	42
215	Letter: chronic kidney disease risk in patients with chronic hepatitis B-authorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1324	6.1	

214	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1629-1638	0.7	17
213	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 793-802	13.4	45
212	Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2018</b> , 15, 461-478	24.2	206
211	Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 76-85	5.3	51
210	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. <i>Hepatology</i> , <b>2017</b> , 65, 54-64	11.2	160
209	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1453-1460.e1	6.9	20
208	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1213-1224	6.1	17
207	Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. <i>Lancet, The</i> , <b>2017</b> , 389, 2375-2382	4.0	52
206	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 175-182	6.1	40
205	HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1111-1119	0.7	28
204	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1071-1078	4	5
203	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 577-584	13.4	80
202	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 447-456	6.1	73
201	International incidence and mortality trends of liver cancer: a global profile. <i>Scientific Reports</i> , <b>2017</b> , 7, 45846	4.9	152
200	Reply. <i>Hepatology</i> , <b>2017</b> , 65, 1780	11.2	
199	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1022-1030	13.4	415
198	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1363-1369	4	34
197	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1812-1823	0.7	49

196	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 1001-1010	6.1	37
195	Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181603	3.7	1
194	Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance". <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	
193	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	47
192	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	49
191	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 617-627	6.1	94
190	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 902-908	13.4	84
189	Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection. <i>Current Hepatology Reports</i> , <b>2017</b> , 16, 97-104	1	0
188	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 667-676	4	87
187	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1230-1233	4	14
186	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , <b>2017</b> , 65, 1145-1155	11.2	135
185	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 506-514	4	26
184	How long will it take to eliminate HCC risk in patients with chronic hepatitis B patients with potent antivirals?. <i>AME Medical Journal</i> , <b>2017</b> , 2, 141-141	1	1
183	Advances in the diagnosis and treatment of liver fibrosis. <i>Hepatoma Research</i> , <b>2017</b> , 3, 156	4.3	8
182	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , <b>2016</b> , 65, 1359-68	19.2	271
181	Eliminating hepatitis B virus as a global health threat. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 1313-1314	45.5	13
180	Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 910	6.1	
179	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , <b>2016</b> , 69, 971-984	7.3	15

178	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 802-13	6.1	28
177	Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage. <i>Gastroenterology</i> , <b>2016</b> , 151, 271-7	13.3	41
176	Liver fibrosis and fatty liver in Asian HIV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 411-21	6.1	35
175	A LEAN treatment for non-alcoholic steatohepatitis. <i>Lancet, The</i> , <b>2016</b> , 387, 628-630	4.0	5
174	Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC. <i>AIMS Medical Science</i> , <b>2016</b> , 3, 162-178	0.4	
173	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , <b>2016</b> , 17, 538-546	3.3	25
172	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 848-55	4	106
171	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , <b>2016</b> , 63, 754-63	11.2	68
170	Reply. <i>Hepatology</i> , <b>2016</b> , 64, 1820-1821	11.2	
169	Reply. <i>Hepatology</i> , <b>2016</b> , 64, 685-6	11.2	1
168	Gastroduodenal Involvement in Asymptomatic Crohn's Disease Patients in Two Areas of Emerging Disease: Asia and Eastern Europe. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 1401-1406	1.5	8
167	Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. <i>BMC Gastroenterology</i> , <b>2016</b> , 16, 100	3	4
166	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62 Suppl 4, S298-S305	11.2	11
165	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , <b>2016</b> , 64, 1507-1517	11.2	19
164	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 56-67	18.8	103
163	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 145-53	6.1	19
162	Letter: factors determining liver fibrosis - more to come. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 171-2	6.1	
161	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , <b>2015</b> , 64, 667-72	19.2	148

160	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1306-14; quiz 1315	0.7	164
159	Is obeticholic Acid the solution to nonalcoholic steatohepatitis?. <i>Gastroenterology</i> , <b>2015</b> , 148, 851-2	13.3	5
158	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1190-7	13.4	59
157	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 4138-48	3.1	162
156	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 807-15	13.4	46
155	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1391-6	4	69
154	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1190-9	6.1	7
153	Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 304-12	6.7	46
152	Huge adrenal hemangioma: a rare cause of deceptively high liver stiffness measurement by transient elastography. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, e37-8	6.9	4
151	Histone Deacetylase HDAC8 Promotes Insulin Resistance and $\beta$ -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , <b>2015</b> , 75, 4803-16	10.1	74
150	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 199-208	6.1	41
149	Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 182-9	13.4	104
148	Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 377-385.e5	6.9	6
147	Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 582-90	4	10
146	Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 731-40	6.1	46
145	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , <b>2015</b> , 62, 684-93	11.2	60
144	Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. <i>Disease Markers</i> , <b>2015</b> , 2015, 564057	3.2	62
143	Personalized management of cirrhosis by non-invasive tests of liver fibrosis. <i>Clinical and Molecular Hepatology</i> , <b>2015</b> , 21, 200-11	6.9	28



142	Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 783-90.e1	6.9	42
141	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1040-8	4	6
140	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E1317-25	11.5	392
139	PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 139-46	4	98
138	Higher estimated net endogenous Acid production may be associated with increased prevalence of nonalcoholic Fatty liver disease in chinese adults in Hong Kong. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122406	3.7	18
137	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139310	3.7	56
136	Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 2133-5	3.4	4
135	PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 532-9	6.1	82
134	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 825-34	3.4	29
133	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , <b>2014</b> , 65, 174-86	7.3	18
132	Is antiviral drug-induced hepatitis B surface antigen loss durable?. <i>Gastroenterology</i> , <b>2014</b> , 147, 1435-6	13.3	1
131	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , <b>2014</b> , 59, 986-95	11.2	98
130	Fatty pancreas, insulin resistance, and Eell function: a population study using fat-water magnetic resonance imaging. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 589-97	0.7	140
129	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 254-69	6.1	249
128	Liver injury is common among chronic abusers of ketamine. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1759-62.e1	6.9	36
127	Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 809-15	13.4	25
126	Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 6006-12	5.6	17
125	Current developments in nucleoside/nucleotide analogues for hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2014</b> , 8, 607-22	4.2	33

124	Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 716-26	6.1	11
123	Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 197-208	6.1	47
122	One-stop clinic for ketamine-associated uropathy: report on service delivery model, patientsR characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. <i>BJU International</i> , <b>2014</b> , 114, 754-60	5.6	33
121	Commentary: coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B - authorsRreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1236-7	6.1	2
120	Reply: To PMID 24519364. <i>Hepatology</i> , <b>2014</b> , 60, 1797-8	11.2	1
119	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 883-93	6.1	79
118	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 116-20	4	28
117	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 708-9	13.4	56
116	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 339-45	13.4	173
115	Prediction of fibrosis progression in chronic viral hepatitis. <i>Clinical and Molecular Hepatology</i> , <b>2014</b> , 20, 228-36	6.9	35
114	Tertiary Prevention of HBV-related HCC in Asia. <i>Current Hepatitis Reports</i> , <b>2013</b> , 12, 157-164		1
113	Association between anthropometric parameters and measurements of liver stiffness by transient elastography. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 295-302.e1-3	6.9	48
112	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 1842-8	4	29
111	Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 57-62	4	19
110	Liver stiffness measurement: simplicity is prerequisite for reliability. <i>Gastroenterology</i> , <b>2013</b> , 144, 243-4	13.3	10
109	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. <i>Hepatology</i> , <b>2013</b> , 58, 1537-47	11.2	321
108	Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. <i>Gastroenterology</i> , <b>2013</b> , 144, 933-44	13.3	136
107	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 536-42	13.4	183

106	Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. <i>Radiology</i> , <b>2013</b> , 269, 910-8	20.5	218
105	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 1762-9	4	19
104	Update of liver fibrosis and steatosis with transient elastography (Fibroscan). <i>Gastroenterology Report</i> , <b>2013</b> , 1, 19-26	3.3	70
103	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2332-8	5.1	16
102	Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 517-26	6.1	61
101	Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice. <i>Clinical Liver Disease</i> , <b>2013</b> , 2, 8-10	2.2	2
100	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 979-86	1.6	10
99	Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes. <i>Annals of Surgery</i> , <b>2013</b> , 257, 922-8	7.8	81
98	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 6515-22	5.6	31
97	Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 671-9	1.6	8
96	Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. <i>PLoS ONE</i> , <b>2013</b> , 8, e62885	3.7	205
95	Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 402-412	3.1	15
94	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 256-262	3.1	187
93	Transient elastography: Kill two birds with one stone?. <i>World Journal of Hepatology</i> , <b>2013</b> , 5, 264-74	3.4	64
92	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1326-35	6.1	42
91	Antiviral drug resistance testing in patients with chronic hepatitis B. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 221-31	4	6
90	Commentary: predicting survival in hepatocellular carcinoma patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 680; discussion 681	6.1	1
89	Commentary: time to update the ALT cut-off?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 682-3.	6.1	1

88	Gastroprotective therapy does not improve outcomes of patients with <i>Helicobacter pylori</i> -negative idiopathic bleeding ulcers. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 1124-9	6.9	30
87	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 533-40	13.4	151
86	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 833-9	13.4	184
85	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1363-70	13.4	162
84	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 1057-66	6.1	49
83	Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. <i>Gastroenterology</i> , <b>2012</b> , 142, 513-520.e1	13.3	134
82	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , <b>2012</b> , 32, 271-8	7.9	14
81	Non-invasive algorithms for liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 310-1; discussion 311-3	6.1	1
80	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , <b>2012</b> , 61, 409-15	19.2	328
79	Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1862-71	0.7	244
78	PWE-293 Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general population: randomised controlled trial. <i>Gut</i> , <b>2012</b> , 61, A417.1-A417	19.2	
77	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , <b>2011</b> , 60, 829-36	19.2	183
76	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 236-42	13.4	110
75	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 497; author reply 498	13.4	4
74	On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 165-72	1.6	75
73	Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 1249-57	1.6	86
72	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 300-5	4	109
71	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 1104-12	6.1	134

70	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 972-81	6.1	14
69	Medical therapy for primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1135-6; discussion 1136-7	6.1	1
68	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , <b>2011</b> , 31, 1047-53	7.9	27
67	Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. <i>Neurogastroenterology and Motility</i> , <b>2011</b> , 23, 155-60, e31	4	19
66	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , <b>2011</b> , 60, 1721-7	19.2	205
65	Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 408-14	7	91
64	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 1095-103	6.1	97
63	Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 1059-68	6.1	39
62	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 1323-31	6.1	89
61	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , <b>2010</b> , 59, 969-74	19.2	431
60	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , <b>2010</b> , 59, 277.1-277	19.2	
59	Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1660-5	2.2	336
58	Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 132-8	0.7	47
57	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 145-55	1.6	37
56	Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 3541-7	4	17
55	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2010</b> , 51, 454-62	11.2	790
54	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , <b>2010</b> , 51, 1945-53	11.2	85
53	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. <i>Hepatology</i> , <b>2010</b> , 52, 1232-41	11.2	192

52	Bacterial microbiota profiling in gastritis without <i>Helicobacter pylori</i> infection or non-steroidal anti-inflammatory drug use. <i>PLoS ONE</i> , <b>2009</b> , 4, e7985	3.7	155
51	Efficacy of cap-assisted colonoscopy in comparison with regular colonoscopy: a randomized controlled trial. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 41-6	0.7	106
50	Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. <i>Journal of Clinical Microbiology</i> , <b>2009</b> , 47, 1830-6	9.7	18
49	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 2766-70	7.5	171
48	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 224-9	19.7	16
47	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 387-96	6.1	87
46	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 36-44	3.4	307
45	Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 63-9	4	19
44	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 1002-7	4	85
43	Surrogate end points and long-term outcome in patients with chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 1113-20	6.9	44
42	High incidence of mortality and recurrent bleeding in patients with <i>Helicobacter pylori</i> -negative idiopathic bleeding ulcers. <i>Gastroenterology</i> , <b>2009</b> , 137, 525-31	13.3	99
41	Predictors of treatment response in chronic hepatitis B. <i>Drugs</i> , <b>2009</b> , 69, 2167-77	12.1	30
40	Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 227-33	6.9	59
39	Repeat-screening colonoscopy 5 years after normal baseline-screening colonoscopy in average-risk Chinese: a prospective study. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2028-34	0.7	39
38	Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 1361-6	6.9	69
37	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , <b>2009</b> , 58, 111-7	19.2	168
36	Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound. <i>World Journal of Radiology</i> , <b>2009</b> , 1, 25-36	2.9	10
35	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 489-99	1.6	14



34	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 489-499	1.6	28
33	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 592-8	4	13
32	Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 914-21	4	53
31	Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 1022-6	6.9	23
30	Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 1027-35	6.9	127
29	Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1682-8	0.7	82
28	Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 3071-81	0.7	73
27	High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 177-82	2.2	242
26	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , <b>2008</b> , 28, 79-87	7.9	93
25	Changes in Crohn's disease phenotype over time in the Chinese population: validation of the Montreal classification system. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 536-41	4.5	57
24	Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kDa; PEGASYS). <i>Antiviral Therapy</i> , <b>2008</b> , 13, 555-62	1.6	4
23	Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 571-9	1.6	10
22	Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 571-579	1.6	26
21	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon αa (40 kDa; PEGASYS®). <i>Antiviral Therapy</i> , <b>2008</b> , 13, 555-562	1.6	12
20	Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 1462-8	6.9	271
19	Initial experience of real-time capsule endoscopy in monitoring progress of the videocapsule through the upper GI tract. <i>Gastrointestinal Endoscopy</i> , <b>2007</b> , 66, 1211-4	5.2	30
18	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , <b>2007</b> , 13, 1228-35	4.5	47
17	Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 25, 891-8	6.1	37

16	Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. <i>Lancet, The</i> , <b>2007</b> , 369, 1621-6	4.0	239
15	Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 815-23	1.6	8
14	Virological Response to Different Combination Regimes of Peginterferon $\alpha$ 2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 815-823	1.6	22
13	Cerebellum vasculopathy and normal tension glaucoma in systemic lupus erythematosus: report of a case and review of the literature. <i>Rheumatology International</i> , <b>2006</b> , 27, 101-2	3.6	5
12	Long-term follow-up of patients with obscure gastrointestinal bleeding after negative capsule endoscopy. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1224-8	0.7	145
11	Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 1154-61	6.9	152
10	Prolonged esophageal transit during wireless capsule endoscopy: a series of five cases and analysis of risk factors. <i>Journal of Clinical Gastroenterology</i> , <b>2006</b> , 40, 176	3	3
9	Inter-observer variations on interpretation of capsule endoscopies. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2006</b> , 18, 283-6	2.2	56
8	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 1215-22	6.1	80
7	Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 465-71	1.6	7
6	Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 1041-9	1.6	1
5	Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic Hbeag-Negative Hepatitis B. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 465-471	1.6	23
4	Quantitative Subtyping of Hepatitis B Virus Reveals Complex Dynamics of Ymdd Motif Mutants Development during Long-Term Lamivudine Therapy. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 1041-1050	1.6	5
3	A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 2205-11	0.7	28
2	Molecular virology in chronic hepatitis B: genotypes. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2005</b> , 66, 13-6	0.8	6
1	Anasarca secondary to problems in three organs: one man with three diseases?. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19, 1651-3	4.3	